OF-OF-O SAP6 Rec'd PCT/PTO

CT/PTO 06 JUD 20067

CASE 33568-US-PCT



EV72727424545
Express Mail Label Number

PRESS MAIL" UNDER 37 CFR 1.10

Support Description Control Descrip

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

ISABEL OTTINGER

INTERNATIONAL APPLICATION NO: PCT/EP3004/014433

FILED: 17 DECEMBER 2004

U.S. APPLICATION NO: 10/580,258 35 USC §371 DATE: 24 MAY 2006

FOR: MICROEMULSION PRECONCENTRATE COMPRISING A RENIN

INHIBITOR

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

## **INFORMATION DISCLOSURE STATEMENT**

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Gregory D. Ferraro

Reg. No. 36,134

Attorney for Applicant

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7831

Date:

- 2 -

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

HEORMATION DISCLOSURE CITATION

(Usaseveral sheets if necessary)

ATTY. DOCKET NO. 33568-US-PCT APPLICATION NO. 10/580,258 APPLICANT Isabel Ottinger FILING DATE MAY 24, 2006

Group

#### **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILII	NG DATE
*	AA	2001/0007663	7/12/01	Corswant	424	400		
	AB	2002/0120015	8/29/02	Dennis et al.	514	772.3		
	AC	2002/0077372	6/20/02	Gers-Barlag et al.	516	98		
	AD	2004/0052824	3/18/04	Abou Chacra-Vernet et al.	424	400		
	AE	4,719,239	1/12/88	Muller et al.	514	785		
	AF	5,559,111	9/24/96	Goeschke et al.	514	227.5		
	AG	5,633,226	5/27/97	Owen et al.	514/2	424/400		
	AH	5,646,109	7/8/97	Owen et al.	514/2	424/400		
	Al	5,688,761	11/18/97	Owen et al.	514/2	424/400		
	AJ	5,897,876	4/27/99	Rudnic et al.	424	455		
	AK	5,952,004	9/14/99	Rudnic et al.	424	455		
	AL	5,993,858	11/30/99	Crison et al.	424	490		
	•		FOREIG	ON PATENT DOCUMENTS	•	•		
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
	AM	EP 0 214 501	9/23/92	EP				
	AN	EP 0 448 091	9/25/91	EP				
	AO	EP 0 591 452	4/13/94	EP				
	AP	EP 0597 007	5/18/94	EP				
	AQ	EP 0597 029	5/18/94	EP		,		

*	AR	Database WPI, Section Ch, Week 199749, AN 1997-201987 (18), XP-002323586 & ZA 9 700 4 (ASTRA AB) (1997)					
	AS	Kararli et al., Pharmaceutical Research, Vol. 9, No. 7, pp. 888-893, "Oral Delivery of a Renin Inhibitor Compound Using Emulsion Formulations. (1992).					
	AT	Stanton, Journal of the Renin-Angiotensin-Aldosterone System, Vol. 4, No. 1, pp . 6-10, "Potential of renin inhibition in cardiovascular disease" (2003).					
EXAM	INER	DATE CONSIDERED					

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

# **INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO. 33568-US-PCT APPLICATION NO. 10/580,258 APPLICANT Isabel Ottinger FILING DATE MAY 24, 2006

Group

## **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	A1	5,948,825	9/7/99	Takahashi et al.	514	937	
	A2	6,267,985	7/31/01	Chen et al.	424	451	
	А3	6,271,307	8/7/01	Huff et al.	525	61	
·	A4	6,309,663	10/30/01	Patel et al.	424	450	
	A5	6,375,960	4/23/02	Simonnet et al.	424	401	
	A6	6,419,946	7/16/02	Sonneville et al.	424	427	
	Α7	6,451,339	9/17/02	Patel et al.	424	451	
	A8	6,541,018	4/1/03	Simonnet et al.	424	401	
	A9	7,060,285	6/13/06	Muller	424	400	
						-	
				·			
						`	
-							

**EXAMINER** 

DATE CONSIDERED

<sup>\*</sup>EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 33568-US-PCT APPLICATION NO. 10/580,258 APPLICANT Isabel Ottinger FILING DATE MAY 24, 2006

Group

#### **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
	CA	EP 0753 311	1/15/97	EP	· · ·			
	СВ	EP 1 170 003	1/9/02	EP	1			
*	СС	EP 1 312 379	5/21/03	EP	1			
*	CD	GB 2 222 770	3/21/90	GB				
	CE	WO 02/09764	2/7/02	wo				
<del></del>	CF	WO 00/33862	6/15/00	wo	<u> </u>			
	CG	WO 00/67888	11/16/00	wo				
	СН	WO 01/28555	4/26/01	wo				
	CI	WO 01/68139	9/20/01	wo				
•	CJ	WO 02/064166	8/23/02	wo				
	СК	WO 02/09671	2/7/02	wo				
	CL	WO 02/09764	2/7/02	wo				
	СМ	WO 03/068186	8/21/03	wo				
	CN	WO 90/08537	8/9/90	wo				
	СО	WO 93/02664	2/18/93	wo				
	СР	WO 94/08603	4/28/94	WO .				
*	CQ	WO 94/08605	4/28/94	wo				
	CR	WO 94/08610	4/28/94	wo				
	cs	WO 95/14037	5/26/95	wo				
	СТ	WO 95/24893	9/21/95	wo				
	CU	WO 95/25504	9/28/95	WO				
	CV	WO 95/28920	11/2/95	wo				
	cw	WO 98/00169	1/8/98	wo				
	СХ	WO 98/51280	11/19/98	wo				
	CY	WO 99/43299	9/2/99	wo				
	CZ	WO 99/44732	9/10/99	wo				<u></u>

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

## **INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO. 33568-US-PCT APPLICATION NO. 10/580,258 APPLICANT Isabel Ottinger FILING DATE MAY 24, 2006

Group

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

BN	Derwent Abstract, Dahms et al., WO 9218227, 10/29/1992, "Stable multiple emulsions for cosmetic use, etc. – contains a mixt. Of emulsifiers with low and high HLB values, WPI 1992-350728.
во	Derwent Abstract, Supersaxo et al., WO 200128520, 04/26/2001, "Microemulsion preconcentrate containing triglyceride, fatty acid and surfactant, spontaneously forming emulsion in water, useful as carrier for water-insoluble active agents, e.g. drugs. WPI 2001-397572.
ВР	Derwent Abstract, Morinaga Milk Co., JP 61185332, 08/19/1986, "Stable emulsion for dispersing water in oil – contains high m.pt. lipid(s), emulsifier e.g. fatty acid ester of sorbitan and water" WPI 1986-255932
BQ	Derwent Abstract, Shiseido Co LTD, JP 63126543, 05/30/1988, "Microemulsion for use in medical and cosmetic compens. – comprises more than 2 oils, water and hydrophilic nonionic surfactant, WPI 1988-187881.
BR	Derwent Abstract, Inada et al., WO0059470, 7/16/00, "Oil-in-water emulsions comprise surfactant to increase solubility of drug in oil" WPI 2000-656199/200063
BS	Derwent Abstract, SANKYO CO LTD, JP 4164024, 6/9/92, Prepn. of self-emulsion type fatty compsn. contg. medicine – by dilution of mixt. of e.g. vegetable oil, nonionic surfactant, solvent and medicated cpd. (WPI 1992-239894/199229.
ВТ	Derwent Abstract, NIPPON OILS, JP 61135572, 06/23/1986, "Lipid emulsion – comprises oil contg. tri-saturted glyceride and palmitic acid, water and emulsifier,
BU	Derwent Abstract, Advanced Skin Res Kenkyusho KK, JP 11009988, 01/19/1999, "Water-in-oil type microemulsion – comprising oil, surfactant and water, WPI 1999-146517.
BV	Derwent Abstract, Nikko Chem. KK, , JP 093855, 12/24/91, "Stable oil-water emulsion comprises all soluble surfactant as emulsifier, with all phase dispersed in aq. phase
вw	Derwent Abstract, Shiseido KK, JP 274531, 5/30/88, "Micro emulsion, esp. useful for medical or cosmetic fields – contg. hydrophilic nonionic surfactant, specified oil(s) and water.
EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.